FDA D.I.S.C.O. Burst Edition: FDA approves Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase
Release Date:
Listen to a soundcast of the July 1, 2021 FDA approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who have developed hypersensitivity to E. coli-derived asparaginase.
FDA D.I.S.C.O. Burst Edition: FDA approves Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase